0.00Open7.50Pre Close0 Volume1 Open Interest68.00Strike Price0.00Turnover2910.09%IV-3.33%PremiumNov 29, 2024Expiry Date10.10Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8877Delta0.0199Gamma7.73Leverage Ratio-140.3886Theta0.0000Rho6.86Eff Leverage0.0006Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet